StockMarketWire.com - Omega Diagnostics said it had CE-marked its disease test for monitoring people living with HIV.

The Visitect CD4 advanced disease test utilised a cut-off of 200 CD4 cells per millimetres cubed of blood, a level at which patients' immune systems are so weakened by HIV that they are at risk of infection by other life-threatening diseases.

'We are pleased to have reached the milestone of attaining the CE-Mark for our test within the timeframe we previously set out,' chief executive Colin King said.

'Together with our currently commercialized Visitect CD4 350 test, we intend to provide easy to use, clinically relevant CD4 testing to less advantaged communities around the world.'

'We look forward to working with the global health community to bring this unique test to the market to make a positive impact on the lives of many people living with HIV.'


At 9:34am: [LON:ODX] Omega Diagnostics Group PLC share price was +0.25p at 13.75p



Story provided by StockMarketWire.com